先健科技公司 （在開曼群島註冊成立的有限公司） 香港交易及結算所有限公司與香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部份內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 LifeTech Scientific Corporation （股份代號：1302） 自願公告 本公司董事（「董事」）會（「董事會」）欣然宣佈，本集團自主研發的IBS®可吸收藥物洗 脫冠脈支架系統（「IBS®冠脈支架」或「本產品」）已順利完成II期臨床研究（「II期臨床 研究」）和III期臨床研究（「III期臨床研究」）兩年隨訪，並於美國當地時間二零二五 年十月二十六至二十七日，由中國醫學科學院阜外醫院宋雷教授代表高潤霖院士和 全體研究者於二零二五年經導管心血管治療年會（「TCT 2025」）向全球公佈IBS®冠 脈支架II期臨床研究的兩年主要終點影像隨訪結果和III期臨床研究的兩年臨床終點 隨訪結果。 IBS®冠脈支架II期臨床研究是一項前瞻性、多中心、單盲、隨機對照臨床研究， 主要研究終點為冠脈支架植入術後兩年病變節段內晚期管腔丟失。II期臨床研究於 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 先健科技公司 (在開曼群島註冊成立的有限公司) 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01302 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 40,000,000,000 | USD | 0.00000125 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 40,000,000,000 | USD | 0.00000125 | USD | | 50,000 ...

LifeTech Scientific Corporation 先 健 科 技 公 司 (Incorporated in the Cayman Islands with limited liability) The English and Chinese versions of the Company's Current Corporate Communication are available on the Company's website at www.lifetechmed.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends that you access the Website Version of Current Corporate Communication. If you have difficult ...

LifeTech Scientific Corporation 先 健 科 技 公 司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） （Stock Code 股份代號：1302） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders, LifeTech Scientific Corporation (the "Company") – Notice of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are now available on the Company's website at www.lifetechmed.com and the website of The Stock E ...

Financial Performance - For the six months ended June 30, 2025, the company reported revenue of RMB 676.7 million, an increase of 3.7% compared to RMB 652.8 million for the same period in 2024[7]. - Gross profit for the same period was RMB 497.8 million, a decrease of 3.4% from RMB 515.4 million in 2024[7]. - Operating profit decreased significantly by 68.1% to RMB 64.4 million from RMB 202.0 million year-on-year[7]. - Net profit attributable to shareholders was RMB 55.1 million, down 73.2% from RMB 205.6 million in the previous year[7]. - The company's revenue for the six months ended June 30, 2025, was approximately RMB 676.7 million, an increase of about RMB 23.9 million or approximately 3.7% compared to RMB 652.8 million in the same period of 2024[17]. - Revenue from the structural heart disease business was approximately RMB 271.5 million, a slight increase of about 0.1% compared to RMB 271.2 million in the same period of 2024, with left atrial appendage occluder sales increasing by approximately 14.7%[18]. - Revenue from the peripheral vascular business was approximately RMB 391.7 million, an increase of about 2.9% compared to RMB 380.7 million in the same period of 2024, with stent sales increasing by approximately 9.6%[20]. - Revenue from the electrophysiology business was approximately RMB 13.5 million, a significant increase of approximately 1,400.0% compared to RMB 0.9 million in the same period of 2024[21]. - The company's gross profit decreased by approximately 3.4% to about RMB 497.8 million, with a gross margin of approximately 73.6%, down 5.3 percentage points from 78.9% in the same period of 2024[22]. Assets and Liabilities - The company’s total assets increased by 8.8% to RMB 5,333.7 million as of June 30, 2025, compared to RMB 4,900.4 million at the end of 2024[7]. - The company’s non-current assets rose by 7.6% to RMB 2,760.4 million, while current assets increased by 10.2% to RMB 2,573.3 million[7]. - The total current liabilities as of June 30, 2025, were approximately RMB 993.3 million, up from RMB 815.6 million as of December 31, 2024, indicating an increase of about 21.8%[42]. - The company’s equity attributable to equity holders as of June 30, 2025, was approximately RMB 3,770.2 million, compared to RMB 3,494.5 million as of December 31, 2024, showing an increase of about 7.9%[47]. - The company’s cash and cash equivalents as of June 30, 2025, were approximately RMB 782.6 million, reflecting a 17.5% increase from RMB 665.8 million as of December 31, 2024[45]. Market and Sales - The domestic market accounted for approximately 74.1% of total revenue, while overseas markets contributed 25.9%[9]. - The company’s overseas sales increased by approximately 8.0% compared to the previous year, driven by active market expansion strategies[9]. - Revenue from Asia (excluding mainland China) and Europe accounted for approximately 11.4% and 11.0% of total revenue, respectively, for the six months ended June 30, 2025, compared to 10.9% and 10.0% in the same period of 2024[57]. Research and Development - Research and development efforts are focused on innovative medical devices to maintain competitive strength and provide better treatment options globally[12]. - The company submitted 73 patent applications and received approval for 41 patents during the six months ended June 30, 2025, bringing the total effective patent applications to 2,464, with 1,123 patents approved and valid[15]. - R&D expenses decreased by approximately 18.2% from RMB 139.9 million to approximately RMB 114.5 million, with total R&D costs dropping about 23.6% to approximately RMB 156.0 million[29]. - Research and development expenses for the period were RMB 114,459,000, reflecting the company's commitment to innovation[157]. - The company has developed a fourth-generation congenital heart disease occluder to meet diverse patient needs, with a focus on innovative technology for left atrial appendage occluders, anticipating continued global market growth due to the large population of atrial fibrillation patients[61]. Expenses and Costs - Sales and distribution expenses increased by approximately 67.3% from RMB 150.0 million for the six months ended June 30, 2024, to approximately RMB 250.9 million for the six months ended June 30, 2025, primarily due to increased employee costs[27]. - Administrative expenses rose by approximately 63.1% from RMB 72.6 million to approximately RMB 118.4 million during the same period, driven by higher employee costs[28]. - The company recognized approximately RMB 33,377,000 in share-based payment expenses for the six months ended June 30, 2025, compared to RMB 40,626,000 for the same period in 2024[195]. Investments - The company has invested RMB 10.0 million in a mixed fund, with the fair value of this investment as of June 30, 2025, being approximately RMB 13.5 million[25]. - The fair value of the company's investment in the 2018 equity fund was approximately RMB 9.2 million as of June 30, 2025, reflecting a positive outlook for the healthcare sector[24]. - The company has agreed to invest a total of RMB 150.0 million in Jianhu Medical Technology (Suzhou) Co., Ltd., acquiring a 30% equity stake upon completion of all investment phases[52]. - The company made an investment of RMB 132,000,000 in an associate company during the period[150]. - The company’s capital injection into Yuanxin Technology totaled RMB 202,000,000 as part of the B round agreement, reducing its equity stake from 57.44% to 49.64%[188]. Corporate Governance - The company has adopted the corporate governance code and has complied with all relevant provisions during the reporting period[78]. - The audit committee, consisting of three independent non-executive directors, has reviewed the interim report and confirmed compliance with accounting standards and legal requirements[82]. - The company is committed to creating value for patients, healthcare institutions, and shareholders through continuous focus on innovation and operational optimization[76]. Employee Information - As of June 30, 2025, the total employee cost, including director remuneration, was approximately RMB 359.6 million, up from RMB 228.2 million in the same period of 2024[64]. - The company has 1,273 full-time employees as of June 30, 2025, a decrease from 1,392 employees as of December 31, 2024[64]. - The company has a comprehensive employee compensation policy that includes performance-based bonuses, transportation and meal allowances, and various insurance benefits[65]. - The company has established a union to protect employee rights and promote stable and healthy development[66]. Share Options and Awards - The total number of options that may be issued under the share option plan is capped at 462,929,240 shares, which is 10% of the issued share capital as of September 17, 2021[94]. - The total number of options granted as of June 30, 2025, is 193,320,000, with 95,309,600 options remaining unexercised[105]. - The company plans to continue its stock option program to incentivize key personnel and align their interests with shareholders[105]. - The 2019 Share Award Scheme aims to retain talent and attract suitable individuals for the group's further development[116]. - The 2022 Share Award Scheme was adopted on March 3, 2022, and aims to recognize and reward contributions from eligible participants[123][124]. Future Outlook - The global medical device industry continues to show significant growth opportunities driven by demographic changes, technological advancements, and increasing healthcare demand[75]. - The company will maintain a focus on international business expansion while ensuring overall operational efficiency and a commitment to technological innovation[75]. - The company plans to continue investing in new technology development and product upgrades to meet evolving market demands[75].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 先健科技公司 (在開曼群島註冊成立的有限公司) 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01302 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 40,000,000,000 | USD | 0.00000125 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 40,000,000,000 | USD | 0.00000125 | USD | | 50,000 | ...

Investment Rating - The report suggests a positive outlook for the medical device industry, indicating that the adjustment period is nearing its end and a recovery is expected in the second half of 2025 [2][4]. Core Insights - The medical device sector is experiencing a recovery trend, with domestic bidding demand showing signs of restoration in the second half of 2025 after a significant decline due to policy delays [2]. - The medical consumables segment is steadily growing, with a slight increase in gross margin, indicating resilience in demand related to patient treatment needs [2]. - The in-vitro diagnostics sector is under pressure, but there is potential for increased domestic market share for local manufacturers in the long term [2]. - Leading medical device companies are accelerating their overseas market expansion, with many reporting higher growth rates in international markets compared to domestic ones [2]. Summary by Sections Medical Equipment - Revenue for Q2 2025 showed a year-on-year decline of 5.26%, with net profit down 27.93% and gross margin decreasing from 53.07% in Q2 2024 to 49.00% in Q2 2025 [16]. - The industry is expected to reach a turning point as domestic bidding demand recovers [2][18]. Medical Consumables - Q2 2025 revenue increased by 1.33% year-on-year, with net profit down 6.28% and a slight improvement in gross margin from 42.13% to 42.24% [23]. - The segment is characterized by stable growth, with companies focusing more on R&D and innovative products [2]. In-Vitro Diagnostics - Revenue for Q2 2025 decreased by 16.53% year-on-year, with net profit down 37.58% and gross margin declining from 62.43% to 59.66% [29]. - The sector faces short-term demand pressure but may benefit from increased domestic production rates in the long run [2]. Investment Recommendations - The report recommends focusing on three key areas: companies leading in international market product and channel expansion, domestic medical device industry leaders, and high-value consumables firms with strong innovation capabilities [34]. - Specific companies to watch include Nanwei Medical, Mindray Medical, Sanofi, and Xinjiang Technology [34].

Core Insights - The company reported a revenue of approximately RMB 676.7 million for the six months ending June 30, 2025, representing a year-on-year increase of about 3.7% [1] - The net profit attributable to shareholders increased by approximately 2.1% to around RMB 238.5 million, compared to RMB 233.6 million in the same period last year, after excluding certain non-recurring items [1] - The company submitted 73 patent applications during the period, with 41 patents successfully approved, highlighting its commitment to intellectual property as a key driver of competitiveness in the medical device market [1] Financial Performance - Domestic sales increased by approximately 2.2% compared to the same period in 2024, while overseas sales grew by about 8.0%, attributed to the company's proactive overseas expansion and effective marketing strategies [1] - Non-recurring items included other income from financial assets measured at fair value of approximately RMB 9.9 million, down from RMB 32.9 million in the same period of 2024, and share-based payment expenses of approximately RMB 193.5 million, up from RMB 61.3 million in 2024 [1] Future Outlook - The company will continue to focus on international business expansion while maintaining overall operational efficiency [2] - There is a strong commitment to technological innovation, with ongoing investments in new technology development and product upgrades to meet changing market demands [2] - The company aims to maintain a prudent capital allocation strategy to ensure sustainable growth and create value for all stakeholders [2]

Core Viewpoint - The company reported a revenue increase of approximately 3.7% year-on-year for the first half of 2025, driven by sales of coated stents and left atrial appendage occluders, despite a significant decline in net profit due to non-recurring items [1] Financial Performance - Revenue for the first half of 2025 was approximately 677 million, an increase of about 3.7% year-on-year [1] - Gross profit was approximately 498 million, representing a year-on-year decrease of about 3.4% [1] - Profit attributable to shareholders was 55.074 million, a significant decrease of 73.21% year-on-year [1] - Earnings per share were 1.3 cents [1] Margin Analysis - Gross margin decreased by 5.3 percentage points year-on-year to approximately 73.6% [1] - The decline in gross margin was attributed to the impact of centralized procurement policies, which led to a decrease in sales prices for certain products in specific regions, as well as changes in the sales mix [1]

Core Points - The company, Xianjian Technology (01302), reported a mid-year revenue of approximately 677 million, representing a year-on-year increase of about 3.7% [1] - Gross profit was approximately 498 million, showing a year-on-year decrease of about 3.4% [1] - Profit attributable to shareholders was 55.074 million, a significant year-on-year decrease of 73.21%, with earnings per share at 1.3 cents [1] Revenue and Profit Analysis - The increase in revenue was primarily driven by higher sales of coated stents and left atrial appendage occluders [1] - The gross profit margin decreased by 5.3 percentage points year-on-year to approximately 73.6%, mainly due to the impact of centralized procurement policies leading to a decline in sales prices of certain products in specific regions, as well as changes in the sales mix [1] - The decrease in net profit was mainly attributed to fluctuations in non-recurring items [1]